Full Breakdown
New Combination Therapy Shows Promise for Permanent HIV Clearance in Newborns
8/11/2026, 3:49:46 AM
Study Overview
Researchers at Oregon Health & Science University (OHSU) reported that a one-time, three-part regimen administered within three days of birth eliminated detectable HIV in nonhuman primate newborns. The regimen combined broadly neutralizing antibodies, standard antiretroviral therapy, and the experimental monoclonal antibody leronlimab. The findings were published in *Nature Microbiology* and, according to the investigators, could move to human clinical trials “immediately.”
Scientific Rationale
Leronlimab is designed to block the CCR5 surface protein that HIV uses to enter immune cells. The researchers observed that the combined approach was markedly more effective than any single component, suggesting a synergistic interaction early in infection.
Implications and Next Steps
Globally, more than 120,000 newborns contract HIV each year, and lifelong treatment remains the standard of care. If the regimen proves safe and effective in humans, it could replace chronic therapy for infants and potentially reduce the annual death toll of roughly 600,000 people worldwide. The team plans to first test the protocol in newly exposed adults before expanding to newborns, and they are investigating whether the window of efficacy can extend beyond the three-day period studied.
Official Statements & Responses
Sacha emphasized that the result was unexpected, noting “there was no reason to think this would completely clear the virus.” Haigwood described the outcome as “remarkable” and highlighted the importance of early-stage viral dynamics. Both scientists expressed optimism while acknowledging that the precise mechanisms remain unclear.
Verbatim Quotes
- “There was no reason to think this would completely clear the virus," Sacha said.” — Jonah Sacha
- “For reasons we don't understand, HIV really wants to use CCR5 receptors to infect cells,” — Jonah Sacha
- “We only tested out to three days,” — Jonah Sacha
